Lantern Pharma is trading 10.3% lower at $0.90; the offering is relevant context, not a confirmed cause. - Closed September 30, 2026, the offering raised approximately $4 million gross through shares and pre-funded warrants at about $1.09 each. - The deal included warrants to purchase up to 3,669,725 additional shares, creating potential dilution; available reporting does not confirm it caused the October 2 decline. - Major indices were higher; no distinct October 2 company announcement was found.